← Back to patent-cliff list
Etrinabdione
Tier C — Watch / tradeEtrinabdione
Vivacell Biotechnology
Originator
-
First approval
-
Expiry (public)
No sales data
Peak sales
Small molecule
Type
Targets：PPARγ, CB2
Indications (approved)：Peripheral arterial disease, 弥漫性硬皮病, Relapsing-remitting multiple sclerosis
Regional status
US
No progress
2020-06-11
EU
Phase II
2026-01-01
China
-
Japan
-
Synthetic routes & intermediates
Routes not yet onboarded — the daily pipeline enriches by priority (approved small molecules first); this page updates automatically.
Frequently asked questions
What are the approved indications of Etrinabdione?
Approved indications include: Peripheral arterial disease, 弥漫性硬皮病, Relapsing-remitting multiple sclerosis.
When does the Etrinabdione patent expire?
No public expiry year is available for Etrinabdione yet; this page updates once verified.
How do I get a quote for Etrinabdione intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-07